培美曲塞二钠联合顺铂治疗晚期肺腺癌的临床研究

目的：探讨培美曲塞联合顺铂治疗晚期肺腺癌的临床疗效及毒性反应。方法：选取晚期肺腺癌患者96例，随机分为PP组与TP组，PP组采用培关曲塞联合顺铂治疗，TP组采用多西他赛联合顺铂治疗，对比两组患者的疾病进展时间（TTP）、生存期（OS）和毒性反应。结果：PP组Ⅲ～Ⅳ度白细胞减少病例少于TP组（P〈0．05），III～Ⅳ度血小板减少病例少于TP组（P〈0．05），两组疗效和生存率比较差异无统计学意义（P〉0．05）。结论：两种方案治疗晚期肺腺癌均具有较好的耐受性和临床疗效，应根据患者临床特点，选择个体化治疗。

Effect of combined therapy of pemetrexed disodium and cis-platinum in treating advanced lung adenocarcinoma

Objective： To discuss the clinical efficacy and toxic reaction of combined therapy of pemetrexed disodium and eis-platinum in treating advanced lung adenocarcinoma. Methods： A total of 96 patients with advanced lung adenocarcinoma were enrolled and divided into PP group and TP group ran- domly. Patients in PP group received combined therapy of pemetrexed disodium and eis-platinum while those in TP group adopted combined therapy of docetaxel and cis-platinum. Time to progress, overall re- sponse and toxic reaction in two groups were observed for comparison. Results： Reduction of white blood cell of III-Ig degrees in PP groups was smaller than that in TP group （P~0.05）, while reduction of Ill-IV degree blood platelet was smaller than TP group （P〈0.05）. No statistical differences were observed be- tween two groups in efficacy or survival rate （P〈0.05）. Conclusion： Both therapies are with good surviv- ability and clinical efficacy in treating advanced lung adenoearcinoma. Individualized treatment should be chosen according to clinical characteristics of patients,